RT Journal Article SR Electronic T1 Antibiotic susceptibility trend estimation for India based on 2018 to 2021 data from GEARS program JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.09.11.24313502 DO 10.1101/2024.09.11.24313502 A1 Naik, Roshan Ratnakar A1 Kalita, Nehal A1 Maurya, Rajesh Kumar A1 Rajan, Annie YR 2024 UL http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313502.abstract AB Antimicrobial resistance (AMR) continues to be a major public threat due to dwindling supplies of effective antibiotics due to its excessive usage in humans and food producing animals. The objective of our study was to identify and predict future trends in multi-drug resistance amongst enterobacteriaceae and non-enterobacteriaceae family in India for four common broad-spectrum antibiotics. We focussed on four broad spectrum antibiotics levofloxacin, gentamicin, cefepime, and ceftazidime and classified the GEARS program study dataset into sensitive (S), intermediate(I) and resistant (R) isolates based on CLSI breakpoints. Levofloxacin (98.3%) was found to be the most susceptible broad spectrum antibiotic for treatment of non-enterobacteriaceae while it was relatively resistant (56.5%) for enterobacteriaceae treatment. As levofloxacin are among ICMR list of ‘alert antimicrobial agents’,hospitals and clinicans can exercise greater care before prescribing them.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This publication is based on research using Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program data from Venatorx, obtained through https://amr.vivli.org.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. All the relevant data code used for ARIMA prediction can be found at the following GitHub repository: https://github.com/nehalkalita/AMR-analysis https://github.com/nehalkalita/AMR-analysis